SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Thirteenth Five-Year Plan Period.
First-in-Class and First-in-Target
- Units 303 and 305 to 307,
No.15 Science Park West Avenue,
Hong Kong Science Park, Pak Shek Kok,
New Territories, Hong Kong